Skip to main content

Advertisement

Table 1 Shows the distribution of salient clinical characteristics of the different treatment groups at study entry

From: Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

Therapy # Eyes (patients) Age (sda) Male (%) Visus (sda) CRT (sda) DME (%) CRVO (%) Mean # IVI before Treatment duration prior study [months]
Only ranibizumab 182 (144) 80.0 (8.9) 63 (34.6) 64.7 (23.7) 314.3 (100.3) 21 (11.5) 7 (3.8) 8.7 19.5
Only aflibercept 63 (52) 75.1 (9.4) 29 (46.0) 69.4 (18.8) 361.2 (152.3) 8 (12.7) 6 (9.5) 4.7 7.9
p-values   < 0.001 0.107 0.159 0.006 0.806 0.083 0.002 < 0.001
Switching from ranibizumab to aflibercept prior study 160 (128) 77.4 (10.2) 66 (41.3) 65.8 (25.4) 304.0 (86.7) 25 (15.6) 7 (4.4) 27.4 51.3
Switching from ranibizumab to aflibercept during study 45 (36) 76.8 (8.7) 19 (42.2) 66.7 (23.8) 323.2 (93.9) 8 (17.8) 6 (13.3) 9.9 19.1
Miscellaneousb 38 (34) 78.9 (8.5) 10 (26.3) 57.2 (26.7) 302.7 (64.3) 7 (18.4) 2 (5.3) 31.8 63.5
  1. asd = standard deviation
  2. bincluding eyes with various treatment regimens. The largest group consisted of 13 eyes with a double switch from ranibizumab to aflibercept and back to ranibizumab prior to study entry